Drugs / ergometrine
ergometrine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT01236482 | Nov 2010 → May 2011 | — | Hadassah Medical Organization | Unknown | No outcome recorded |
| Phase not applicable2 trials · 1 met primary | ||||||
| — | NCT02046499 | Jan → Jun 2014 | — | University of Pretoria | Completed | No outcome recorded |
| — | NCT01689311 | Mar 2009 → Aug 2011 | — | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Completed | Met primary |
| Comparator or background therapy8 trials | ||||||
| Phase 3 | NCT02410759 Comparator | Apr 2015 → Mar 2017 | — | Cairo University | Unknown | No outcome recorded |
| Phase 3 | NCT02306733 Comparator | Nov 2014 → Oct 2017 | — | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT03693599 Comparator | Oct 2018 → Sep 2019 | — | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT04300452 Comparator | Apr 2018 → Jun 2020 | — | National and Kapodistrian University of Athens | Unknown | No outcome recorded |
| Phase 4 | NCT02044549 Comparator | Jun 2014 → Dec 2015 | — | Cairo University | Completed | No outcome recorded |
| — | NCT06285409 Comparator | Apr 2024 → Dec 2026 expected | — | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Recruiting | No outcome recorded |
| — | NCT03578263 Comparator | Apr 2018 → Mar 2020 | — | Aswan University Hospital | Completed | No outcome recorded |
| — | NCT00989027 Comparator | Jun 2007 → Aug 2013 | — | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ergometrine | “one ampoule of syntometrine (Novartis, Basel, Switzerland), which consisted of 5 IU of oxytocin and 500 microgram of ergometrine diluted in 10 ml of Ringer's lactate solution...” NCT03693599 ↗6“Intravenous combination of 5 IU oxytocin and 0.2 mg ergometrine (300 women) after fetal extraction and before placental removal.” NCT02044549 ↗ |
| Known as | Ergometrine Maleate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04300452 ↗ |
| Known as | Ergonovine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00989027 ↗ |
| Known as | Methergin | “100 women with atonic PPH will receive Ergometrine 400µgm (Methergin® Novartis, Switzerland) slowly intravenous (iv).” NCT02306733 ↗ |
| Known as | Methergine | “group 2 will receive ergometrine 0.5mg (Methergine®, Novartis, Switzerland).” NCT02410759 ↗ |
| Route | Intravenous | “Intravenous combination of 5 IU oxytocin and 0.2 mg ergometrine” NCT02044549 ↗ |